Published online Jul 12, 2013. doi: 10.5499/wjr.v3.i2.9
Revised: April 23, 2013
Accepted: June 1, 2013
Published online: July 12, 2013
Core tip: Rituximab (RTX) may be an effective treatment for systemic sclerosis (SSc)-associated interstitial lung disease (ILD). A large scale study assessing the efficacy of RTX in SSc associated ILD is warranted. If RTX turns out to be effective, it would be a major therapeutic advance in SSc since it can be administered on a long term basis due to its acceptable safety profile.